Studies how antiseizure medicines work and their safety in older adults
Studies antiseizure medicines in people aged 65 to 100 with epileptic seizures.
Plain-language title generated from the registry record
Registry title: Antiepileptic Drugs in Elderly Patients
Key facts
- Where
- Jinan, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 65 and over who have epilepsy and are being treated with antiepileptic drugs.
- Age
- 65 to 100 years
- Sex
- Men and women
- Disease stage
- Diagnosed with epilepsy.
- Earlier treatment
- Must be using antiepileptic drugs for treatment.
Main reasons for not taking part
- Expected to die within 48 hours
- Allergy to antiepileptic drugs
- Receiving other investigational drugs
- Other factors the researcher considers unsuitable for inclusion
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 65 and 100 years old?
Source: NCT05459597, who can take part
Where in China
- Wei ZhaoJinan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wei Zhao
- Trial code
- NCT05459597
- Record updated
- 15 July 2022
- Original description
The purpose is to study the population pharmacokinetics, effectiveness and safety of antiepileptic drug (phenytoin, carbamazepine, lamotrigine, levetiracetam, parempanel, etc) in elderly patients and recommend optimized dosage regimens.Read full original descriptionShow less
Population Pharmacokinetics, Effectiveness and Safety of Antiepileptic Drugs in Elderly Patients
The purpose is to study the population pharmacokinetics, effectiveness and safety of antiepileptic drug (phenytoin, carbamazepine, lamotrigine, levetiracetam, parempanel, etc) in elderly patients and recommend optimized dosage regimens.
Inclusion: Age ≥65 years old; Diagnosed with epilepsy; Using antiepileptic drugs for treatment.
Exclusion: Patients receiving other investigational drugs; Patients with allergy to antiepileptic drugs; Patients who are expected to die within 48 hours; Other factors that the researcher considers unsuitable for inclusion.